Francois Martelet named CEO of TopoTarget

> TopoTarget has reported that Francois Martelet will become the company's CEO to add the necessary late-stage clinical development and marketing expertise to ensure the successful development and commercialization of belinostat, its lead anticancer drug. Release

> Jeffrey Buchalter has resigned as CEO of Enzon Pharmaceuticals and been replaced by a newly formed executive committee of the board. Release

> Sepracor President and CEO Adrian Adams has left the company to become the CEO of Inspire Pharmaceuticals. Release | Release

> Transdel Pharmaceuticals President and CEO Juliet Singh has resigned. Jeffrey Abrams has been appointed as chairman of the board, while CFO John Lomoro will serve as acting CEO. Release

> Protein Sciences has adopted a succession plan through which COO Manon Cox will become president and CEO as of March 1.  Current Chairman, President and CEO Daniel Adams will assume the role of executive chairman. Release

>  Richard Kent is set to join Aldagen's board of directors as chairman. Aldagen also has announced the appointment of James Hinson, Jr., as CMO. In addition, Tom Amick will serve as Aldagen's president and CEO, and Edward  Field will become EVP and chief business officer. Release

> GeneLink BioSciences has appointed Gary Beeman as its president and CEO. Release

> iPierian has tapped Michael Venuti as president and chief scientific officer. Release

> Tarsa Therapeutics has added two executives to its senior management team. David Krause has joined the company as CMO, and Thomas Wicks has come on board as VP, global regulatory affairs. Release

> Liquidia Technologies announced that Frank Malinoski has joined the company as CMO. Release

> Alexza Pharmaceuticals has promoted Mark Oki has been named VP, finance and controller. Release

> Acorda Therapeutics has announced that Adrian Rabinowicz has joined the company as SVP and head, medical affairs. Release

> Topica Pharmaceuticals has appointed Mark Davis as VP of clinical development. Release

> Reginald Hardy, the president of Concordia Pharmaceuticals, has been appointed as a director on the board of Neurologix. Release

> A.P. Pharma has appointed Stephen Davis to its board of directors. Davis was the CEO of Neurogen, which was recently acquired by Ligand Pharmaceuticals. Release

> Cubist Pharmaceuticals has named Leon (Lonnie) Moulder, Jr., the former vice chairman, president and CEO of Abraxis BioScience, to its board of directors. Release

> Michel Lagueux has resigned his position as non-executive director at PharmaForm, a wholly owned subsidiary of Akela Pharma. Release

> QLT has appointed Joseph Turner to the company's board of directors and audit and risk committee. Release

> William Rohn has joined Intellikine's board of directors. Release

> Immunovaccine has appointed James Hall to its board of directors. He will serve as chair of Immunovaccine's audit committee.

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.